Eloxx Pharmaceuticals, Inc. announced recent developments in their programs for ELX-02 and ZKN-013, highlighting the Orphan Drug Designation awarded to ELX-02.

On April 5, 2024, the 2024 AACR present the updated data from a Phase 2 expansion cohort for patients (pts) with advanced NSCLC.

In the TOPAZ-1 Phase III trial, the combination of Imfinzi and chemotherapy increased the three-year overall survival rate by twofold in patients with advanced biliary tract cancer.

Toxoids and antitoxins are distinct biological products used to prevent and treat toxin-related bacterial diseases, differing in origin, preparation, and function.

Neurona Therapeutics Reports Encouraging Results from Its NRTX-1001 Cell Therapy Study in Adults Suffering from Drug-resistant Focal Epilepsy at the 2024 AAN Annual Meeting.

On April 5, 2024, the final results of the first-in-human study of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in patients with advanced solid tumors were reported in 2024 AACR.

TransCode Therapeutics has received FDA approval to start a Phase 1/2 clinical trial of TTX-MC138 in patients with advanced solid tumors.

Medincell and AbbVie Partner to Co-Develop Six Long-Acting Injectables.

The main differences between IIT (Investigator Initiated Trial) clinical trials and other types of clinical trials lie in aspects such as the initiator, purpose, funding source, and regulatory requirements.

On April 7, 2024, the latest clinical data of ociperlimab + tislelizumab + cCRT in patients with untreated limited-stage SCLC was reported in 2024 AACR.

Latest findings from Novartis on Fabhalta® (iptacopan) reveal a notable and statistically significant decrease in proteinuria by 38.3% compared to placebo in individuals suffering from IgA nephropathy (IgAN).

On April 10, 2024, Vertex Pharmaceuticals ("Vertex") and Alpine Immune Sciences ("Alpine") announced that the parties entered into a definitive agreement. the parties have entered into a definitive agreement.